ArticleTranslational vision science & technology2019
Efficacy and Safety of Transglutaminase-Induced Corneal Stiffening in Rabbits.
Article in Translational vision science & technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 20 citations in OpenAlex.
- Progressive Insights into 3D Bioprinting for Corneal Tissue Restoration.Advanced healthcare materials · 2026Review
- Efficacy of enzyme‑induced collagen crosslinking on porcine cornea.Experimental and therapeutic medicine · 2024Article
- Recent advances in medicinal compounds related to corneal crosslinking.Frontiers in pharmacology · 2023Review
- Mechanical Properties of Bioengineered Corneal Stroma.Advanced healthcare materials · 2021Review
- Biomechanics of Ophthalmic Crosslinking.Translational vision science & technology · 2021Review
- Advances in the diagnosis and treatment of keratoconus.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the biomechanical efficacy and safety of in vivo microbial transglutaminase (Tgases)-induced corneal crosslinking in a rabbit model.
methodsA total of 34 white New Zealand rabbits were divided into two groups, a biochemistry group and a photochemistry group. The right eye of every rabbit was treated and left eyes served as negative controls. In the biochemistry group, a 1 U/mL solution of crosslinking agent microbial Tgases (Tgases CXL) was applied to the corneal surface, while in the photochemistry group, clinical ultraviolet A-riboflavin crosslinking (UVA/RF CXL) was used. Efficacy and safety evaluated on the 14th day after the procedures. Twelve pairs of corneal strips were harvested from the eyes of 12 euthanized rabbits in every group, and uniaxial tensile tests were performed to evaluate ex vivo biomechanical effects. The CXL-treated eye to its corresponding untreated eye ratio of tangent modulus were calculated. Another five pairs of corneal button were excised from euthanized animals in every group for corneal stroma and endothelium staining to evaluate changes in keratocyte distribution and endothelial cell damage.
resultsIn tensile tests, tangent modulus was statistically higher in the Tgases CXL groups under 1.0 MPa (26.59 ± 4.54 vs. 21.47 ± 4.72 MPa,
conclusionsTgases-CXL effectively stiffened the cornea and caused no damage to the endothelium and keratocytes in the cornea. This crosslinking method could be useful as a next-generation treatment for corneal ectasia and could replace CXL of photochemistry. TRANSLATIONAL RELEVANCE: These findings may give a new hope to biomechanically compromised corneal disease due to mechanical forces, such as corneal ectasia and keratoconus. A next-generation treatment to these corneal diseases due to mechanical forces may be designed based on the new findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.